KVUE stock closes at $18.18 on 11 Feb 2026: earnings week to watch

Kenvue (KVUE) closed at $18.18 on 11 Feb 2026 as investors positioned ahead of the company’s upcoming earnings report. The stock traded 91,503,300 shares intraday and sits well below its 52-week high of $25.17. With an earnings announcement set for 17 Feb 2026, KVUE stock movement this week will reflect guidance clarity, dividend signals and retailer demand trends.

KVUE stock: earnings schedule and what matters

Kenvue reports results on 17 Feb 2026 (after the close). Investors will focus on organic sales trends in Self Care and Skin Health and updated margin guidance. One clear near-term catalyst is the dividend record and payout pattern; the company set an ex-dividend date of 11 Feb 2026 and a quarterly payout of $0.2075.

Earnings beats or misses should move KVUE stock toward short-term price levels near the 50-day average $17.29 or the 200-day average $19.24.

KVUE stock: key financials and valuation

Kenvue reports trailing EPS of $0.75 and a trailing P/E of 24.67. The company carries a market cap near $35.46B and a dividend yield around 4.48% with a payout ratio of 110.67%. These metrics show an income profile but a stretched payout relative to earnings.

On balance-sheet measures, debt-to-equity is about 0.86 and the current ratio is 0.98, which implies modest leverage and tight working capital. Price-to-sales is 2.36 and price-to-book is 3.33, placing KVUE stock in the mid-range of consumer defensive valuations.

KVUE stock: technicals and trading flow

Price action shows a recent close at $18.18, day range $17.98–$18.21, and average volume of 44,320,054 shares versus today’s 91,503,300. Short-term momentum is muted: RSI 43.30 and ADX 18.62 indicate no dominant trend.

Technicals imply earnings volatility could widen the range toward the Bollinger upper band near $17.51 or the lower band near $16.76, depending on the print and forward commentary.

KVUE stock: analyst views and institutional moves

Street coverage shows more Hold ratings than Buys; consensus target sits near $19.46. Recent filings show large institutional turnover: Oppenheimer and others trimmed stakes while some funds expanded positions in successive quarters. MarketBeat and Investing.com list recent filings and target updates MarketBeat news and historical price data Investing.com KVUE price history.

Insider activity includes Director purchases (3,200,000 shares at $17.37), a notable bullish signal ahead of earnings.

KVUE stock: risks, opportunities and sector context

Kenvue sits in the Consumer Defensive sector, which typically outperforms in market stress but trails in cyclical rebounds. Opportunities include steady brand cash flow from Tylenol, Neutrogena and Listerine and a 4.48% yield attractive to income investors.

Risks are slow organic growth, high payout pressure (payout ratio 110.67%), and supply or retail-channel headwinds that would compress margins and push KVUE stock lower.

KVUE stock: Meyka grade and model view

Meyka AI rates KVUE with a score out of 100: 72.38 (B+), Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade is informational and not investment advice.

Meyka AI’s forecast model projects a monthly price of $21.36, a quarterly price of $15.23, and a yearly price of $10.22. These model outputs reflect scenario-weighted outcomes and hinge on earnings cadence and dividend sustainability.

Final Thoughts

Kenvue (KVUE) enters earnings week trading at $18.18 with clear near-term catalysts: the 17 Feb 2026 earnings release, a recent dividend declaration, and active institutional rebalancing. The company shows steady brand cash flow and a high dividend yield 4.48%, but the payout ratio 110.67% and slowing EPS growth create real headline risk. Meyka AI’s forecast model projects a monthly target of $21.36, implying an upside of 17.54% versus the current price $18.18, while the quarterly projection of $15.23 implies a short-term downside of -16.25%. Forecasts are model-based projections and not guarantees. For traders, watch guidance and margin commentary; for income investors, monitor dividend coverage. Use Meyka AI’s market analysis and the linked MarketBeat and Investing.com reports to cross-check filings and price history before taking action.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.